Anoro Ellipta 55micrograms / dose / 22micrograms / dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose

Type Dry powder inhaler (DPI)
Medicine Umeclidinium bromide 65micrograms/dose + Vilanterol 22micrograms/dose
Activation mechanism Breath actuated
Dose counter Has dose counter
Price £32.50 / 30 days
(based on 1 puffs / day)
Licences
  • COPD Licence

Training material

Pathways

The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.

Prescribing

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Dosing

Chronic obstructive pulmonary disease

Type Age Range Dose Licensed
Maintenance From 18 years 1 actuation - ONCE a DAY - inhalation - using a metered dose device

Safety Advice Warnings

Adverse effects (report/action)

  • May reduce serum potassium levels

Advice on possible excipients

  • Contains lactose

Discontinue due to test or exam

  • Discontinue if paradoxical bronchospasm occurs

Patient Counselling

  • Advise patient not to use for relief of acute attacks
  • Advise patient to seek medical advice if treatment is ineffective
  • Ensure patient has a fast acting bronchodilator available
  • Use regularly to maintain freedom from symptoms

Recommended monitoring

  • Check patient is using correct inhaler technique
  • Monitor blood glucose closely in patients with diabetes mellitus
  • Monitor serum K+ in patients on high dose steroids/xanthines/diuretics

Drug Interactions

With Risk Severity
AMANTADINE Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ANTIHISTAMINES - SEDATIVE Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CODEINE Antimuscarinic side effects may be increased/risk of paralytic ileus Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CYCLIZINE (IN COMBINATION WITH STRONG OPIOIDS) Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DISOPYRAMIDE Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
MAOIS Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
NEFOPAM Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
TRICYCLIC ANTIDEPRESSANTS Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINES (COMBINED PRODUCT) Antimuscarinic side effects may be increased Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AMISULPRIDE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ARIPIPRAZOLE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
BENPERIDOL Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
CLOZAPINE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
DROPERIDOL Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
FLUSPIRILINE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
HALOPERIDOL Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
LOXAPINE (INHALED) Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
LOXAPINE (ORAL) Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
MEMANTINE effect may be increased by Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
OLANZAPINE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
OXYPERTINE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
PALIPERIDONE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
PHENOTHIAZINES Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
PIMOZIDE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
QUETIAPINE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
REMOXIPRIDE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
RISPERIDONE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
SERTINDOLE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
SULPIRIDE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
TRIFLUPERIDOL Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ZIPRASIDONE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ZOTEPINE Antimuscarinic side effects may be increased Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.

Precautions

  • Benign prostatic hyperplasia
  • Bladder outflow obstruction
  • Diabetes mellitus
  • Epileptic disorder
  • Glucose-galactose malabsorption syndrome
  • Hypokalaemia
  • Lactose intolerance
  • Narrow angle glaucoma
  • Pregnancy
  • Severe cardiovascular disorder
  • Severe hepatic impairment
  • Thyrotoxicosis
  • Urinary retention

Contraindications

  • Breastfeeding
  • Children under 18 years
  • Galactosaemia

Side Effects

  • Anaphylaxis
  • Angioedema
  • Atrial fibrillation
  • Bladder outflow obstruction
  • Blurred vision
  • Bronchospasm (paradoxical)
  • Constipation
  • Cough
  • Dry mouth
  • Dysgeusia
  • Dysphonia
  • Dysuria
  • Glaucoma
  • Headache
  • Hypersensitivity reactions
  • Hypokalaemia
  • Increased intra-ocular pressure
  • Nasopharyngitis
  • Oropharyngeal pain
  • Palpitations
  • Pharyngitis
  • Rash
  • Rhythm idioventricular
  • Sinusitis
  • Supraventricular tachycardia
  • Tachycardia
  • Tremor
  • Upper respiratory tract infection
  • Urinary retention
  • Urinary tract infections
  • Urticaria
  • Ventricular extrasystoles